Dallah 9M 2024 profit soars 45% to SAR 357.3M; Q3 at SAR 126.2M

10/11/2024 Argaam Exclusive

View other reports

Dallah Healthcare Co. reported a net profit of SAR 357.31 million in the first nine months of 2024, an increase of 45% from SAR 246.5 million a year earlier.

Financials (M)

Item	9m 2023	9m 2024	Change‬
Revenues	2,136.89	2,396.97	12.2 %
Gross Income	782.73	914.08	16.8 %
Operating Income	371.97	451.72	21.4 %
Net Income	246.47	357.30	45.0 %
Average Shares	97.68	97.68	-
EPS (Riyals)	2.52	3.66	45.0 %

The profit rise was driven by a 12.2% increase in revenue to SAR 2.4 billion from SAR 2.1 billion a year earlier, due to the expansion in the operational capacity and the continuing growth in the number of patients in the group’s hospitals.

The improvement in the performance of associates led to a profit of SAR 28 million during the period, against losses of SAR 5 million in the same period of the prior year.

Current Quarter Comparison (M)

Compared With The

Item	Q3 2023	Q3 2024	Change‬
Revenues	749.83	847.73	13.1 %
Gross Income	280.86	322.99	15.0 %
Operating Income	130.97	161.42	23.3 %
Net Income	98.87	126.16	27.6 %
Average Shares	97.68	97.68	-
EPS (Riyals)	1.01	1.29	27.6 %

Item	Q2 2024	Q3 2024	Change‬
Revenues	765.18	847.73	10.8 %
Gross Income	297.73	322.99	8.5 %
Operating Income	141.07	161.42	14.4 %
Net Income	111.84	126.16	12.8 %
Average Shares	97.68	97.68	-
EPS (Riyals)	1.14	1.29	12.8 %

The third-quarter net profit rose to SAR 126.2 million, up 28%, from SAR 98.9 million in Q3 2023.

The net profit improved 12.8% from SAR 111.8 million in Q2 2024.

Shareholders’ equity, after excluding minority interest, rose to SAR 3.41 billion as of Sept. 30, 2024, from SAR 3.18 billion a year earlier.

Dallah signed, on Aug. 19, a binding acquisition and subscription agreement with AYYAN Investment Co. to purchase the latter’s stakes in Al-Ahsa Medical Services Co. and Al-Salam Medical Services Co.

The agreement included acquiring 97.4% of the capital of Al-Ahsa (which owns Al-Ahsa Hospital in Al-Ahsa) and 100% of the capital of Al-Salam (which owns Al-Salam Hospital in Al-Khobar).

On Sept. 19, Dallah and AYYAN announced the issuance of a no-objection from the General Authority for Competition (GAC) to complete the economic concentration process.

Attached Document:

View more financial results

Financial results (Million)

Period	Revenues	Change	Gross Income	Change	Operating Income	Change
Q1 2015	240.40	15.8 %	102.13	16.6 %	39.67	(0.1 %)
Q2 2015	245.23	11.7 %	100.89	7.6 %	35.71	6.7 %
Q3 2015	223.93	16.2 %	87.92	16.7 %	26.37	21.7 %
Q4 2015	276.50	15.2 %	116.81	12.8 %	57.01	13.5 %
2015	985.44	14.8 %	407.14	13.5 %	160.78	10.8 %
Q1 2016	285.03	18.6 %	132.53	29.8 %	61.90	56.1 %
Q2 2016	288.35	17.6 %	129.78	28.6 %	59.34	66.2 %
Q3 2016	273.17	22.0 %	122.38	39.2 %	51.80	96.4 %
Q4 2016	316.24	14.4 %	151.01	29.3 %	57.96	1.7 %
2016	1,162.79	18.0 %	535.70	31.6 %	231.00	43.7 %
Q1 2017	302.75	6.2 %	143.60	8.4 %	85.82	38.6 %
Q2 2017	288.20	0.0 %	130.48	0.5 %	70.86	19.4 %
Q3 2017	295.25	8.1 %	136.77	11.8 %	76.36	47.4 %
Q4 2017	325.87	3.0 %	148.23	(1.8 %)	74.95	29.3 %
2017	1,212.08	4.2 %	559.08	4.4 %	307.98	33.3 %
Q1 2018	308.59	1.9 %	131.73	(8.3 %)	59.44	(30.7 %)
Q2 2018	273.13	(5.2 %)	92.38	(29.2 %)	19.67	(72.2 %)
Q3 2018	280.94	(4.8 %)	101.37	(25.9 %)	33.44	(56.2 %)
Q4 2018	318.28	(2.3 %)	110.86	(25.2 %)	33.04	(55.9 %)
2018	1,180.94	(2.6 %)	436.34	(22.0 %)	145.59	(52.7 %)
Q1 2019	321.15	4.1 %	120.26	(8.7 %)	41.24	(30.6 %)
Q2 2019	286.00	4.7 %	92.46	0.1 %	18.06	(8.2 %)
Q3 2019	301.34	7.3 %	107.78	6.3 %	30.99	(7.3 %)
Q4 2019	343.60	8.0 %	127.34	14.9 %	64.09	94.0 %
2019	1,252.09	6.0 %	447.85	2.6 %	154.39	6.0 %
Q1 2020	314.61	(2.0 %)	105.76	(12.1 %)	26.42	(35.9 %)
Q2 2020	247.56	(13.4 %)	67.77	(26.7 %)	7.97	(55.9 %)
Q3 2020	350.79	16.4 %	132.62	23.0 %	50.51	63.0 %
Q4 2020	405.30	18.0 %	143.57	12.7 %	40.26	(37.2 %)
2020	1,318.25	5.3 %	449.73	0.4 %	125.16	(18.9 %)
Q1 2021	494.67	57.2 %	176.82	67.2 %	72.91	176.0 %
Q2 2021	490.83	98.3 %	168.17	148.1 %	68.57	760.1 %
Q3 2021	544.12	55.1 %	192.46	45.1 %	69.95	38.5 %
Q4 2021	575.57	42.0 %	222.91	55.3 %	116.48	189.4 %
2021	2,105.18	59.7 %	760.36	69.1 %	327.92	162.0 %
Q1 2022	609.40	23.2 %	231.69	31.0 %	109.93	50.8 %
Q2 2022	583.82	18.9 %	212.13	26.1 %	96.68	41.0 %
Q3 2022	600.89	10.4 %	211.47	9.9 %	84.19	20.4 %
Q4 2022	693.88	20.6 %	239.81	7.6 %	101.69	(12.7 %)
2022	2,487.98	18.2 %	895.10	17.7 %	392.49	19.7 %
Q1 2023	716.64	17.6 %	266.79	15.1 %	132.49	20.5 %
Q2 2023	670.42	14.8 %	235.08	10.8 %	87.85	(9.1 %)
Q3 2023	749.83	24.8 %	280.86	32.8 %	130.97	55.6 %
Q4 2023	806.01	16.2 %	295.94	23.4 %	126.50	24.4 %
2023	2,942.90	18.3 %	1,078.67	20.5 %	471.60	20.2 %
Q1 2024	784.06	9.4 %	293.36	10.0 %	143.22	8.1 %
Q2 2024	765.18	14.1 %	297.73	26.7 %	141.07	60.6 %
Q3 2024	847.73	13.1 %	322.99	15.0 %	161.42	23.3 %

Period	Revenues	Change	Gross Income	Change	Operating Income	Change
2014	858.75	14.6 %	358.57	9.5 %	145.09	5.5 %
2015	985.44	14.8 %	407.14	13.5 %	160.78	10.8 %
2016	1,162.79	18.0 %	535.70	31.6 %	231.00	43.7 %
2017	1,212.08	4.2 %	559.08	4.4 %	307.98	33.3 %
2018	1,180.94	(2.6 %)	436.34	(22.0 %)	145.59	(52.7 %)
2019	1,252.09	6.0 %	447.85	2.6 %	154.39	6.0 %
2020	1,318.25	5.3 %	449.73	0.4 %	125.16	(18.9 %)
2021	2,105.18	59.7 %	760.36	69.1 %	327.92	162.0 %
2022	2,487.98	18.2 %	895.10	17.7 %	392.49	19.7 %
2023	2,942.90	18.3 %	1,078.67	20.5 %	471.60	20.2 %

Profit Performance (Million)

Period	Net Income	Change	EPS(Riyal)	Extraordinary Income/Expense	Net Profit Before Unusual Items	EPS Before XO Items
Q1 2015	47.82	18.1 %	0.53	13.75	34.07	0.38
Q2 2015	35.86	4.4 %	0.40	-	35.86	0.40
Q3 2015	26.78	22.1 %	0.30	-	26.78	0.30
Q4 2015	54.60	8.4 %	0.61	-	54.60	0.61
2015	165.06	12.2 %	1.83	13.75	151.31	1.68
Q1 2016	58.07	21.4 %	0.65	(2.02)	60.09	0.67
Q2 2016	54.14	51.0 %	0.60	(3.07)	57.21	0.64
Q3 2016	60.80	127.0 %	0.68	9.42	51.39	0.57
Q4 2016	51.71	(5.3 %)	0.57	(6.00)	57.71	0.64
2016	224.71	36.1 %	2.50	(1.68)	226.39	2.52
Q1 2017	85.05	46.5 %	0.94	-	85.05	0.94
Q2 2017	69.99	29.3 %	0.78	-	69.99	0.78
Q3 2017	76.82	26.3 %	0.85	-	76.82	0.85
Q4 2017	63.12	22.1 %	0.70	(11.69)	74.81	0.83
2017	294.98	31.3 %	3.28	(11.69)	306.67	3.41
Q1 2018	58.09	(31.7 %)	0.65	-	58.09	0.65
Q2 2018	18.73	(73.2 %)	0.21	-	18.73	0.21
Q3 2018	32.48	(57.7 %)	0.36	-	32.48	0.36
Q4 2018	32.47	(48.6 %)	0.36	-	32.47	0.36
2018	141.76	(51.9 %)	1.58	-	141.76	1.58
Q1 2019	35.17	(39.5 %)	0.39	-	35.17	0.39
Q2 2019	15.35	(18.1 %)	0.17	-	15.35	0.17
Q3 2019	26.62	(18.1 %)	0.30	-	26.62	0.30
Q4 2019	69.79	115.0 %	0.78	13.39	56.41	0.63
2019	146.92	3.6 %	1.63	13.39	133.53	1.48
Q1 2020	19.24	(45.3 %)	0.21	-	19.24	0.21
Q2 2020	6.99	(54.4 %)	0.08	-	6.99	0.08
Q3 2020	53.78	102.1 %	0.60	16.36	37.42	0.42
Q4 2020	51.98	(25.5 %)	0.58	34.87	17.11	0.19
2020	132.00	(10.2 %)	1.47	51.23	80.76	0.90
Q1 2021	52.61	173.4 %	0.58	-	52.61	0.58
Q2 2021	47.54	579.9 %	0.53	-	47.54	0.53
Q3 2021	49.85	(7.3 %)	0.55	-	49.85	0.55
Q4 2021	108.60	108.9 %	1.21	10.35	98.25	1.09
2021	258.60	95.9 %	2.87	10.35	248.26	2.76
Q1 2022	82.63	57.1 %	0.92	-	82.63	0.92
Q2 2022	69.52	46.2 %	0.77	-	69.52	0.77
Q3 2022	43.87	(12.0 %)	0.49	-	43.87	0.49
Q4 2022	78.44	(27.8 %)	0.87	-	78.44	0.87
2022	274.46	6.1 %	3.05	-	274.46	3.05
Q1 2023	94.66	14.6 %	0.97	-	94.66	0.97
Q2 2023	53.01	(23.8 %)	0.54	-	53.01	0.54
Q3 2023	98.87	125.4 %	1.01	-	98.87	1.01
Q4 2023	113.65	44.9 %	1.16	-	113.65	1.16
2023	360.12	31.2 %	3.69	-	360.12	3.69
Q1 2024	119.30	26.0 %	1.22	-	119.30	1.22
Q2 2024	111.84	111.0 %	1.14	-	111.84	1.14
Q3 2024	126.16	27.6 %	1.29	-	126.16	1.29

Period	Net Income	Change	EPS(Riyal)	Extraordinary Income/Expense	Net Profit Before Unusual Items	EPS Before XO Items
2014	147.12	7.7 %	1.63	-	147.12	1.63
2015	165.06	12.2 %	1.83	13.75	151.31	1.68
2016	224.71	36.1 %	2.50	(1.68)	226.39	2.52
2017	294.98	31.3 %	3.28	(11.69)	306.67	3.41
2018	141.76	(51.9 %)	1.58	-	141.76	1.58
2019	146.92	3.6 %	1.63	13.39	133.53	1.48
2020	132.00	(10.2 %)	1.47	51.23	80.76	0.90
2021	258.60	95.9 %	2.87	10.35	248.26	2.76
2022	274.46	6.1 %	3.05	-	274.46	3.05
2023	360.12	31.2 %	3.69	-	360.12	3.69

Profitability

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
Q1 2015	41.98 %	21.38 %	15.76 %
Q2 2015	41.58 %	21.72 %	15.48 %
Q3 2015	41.54 %	21.77 %	15.49 %
Q4 2015	41.35 %	21.81 %	15.34 %
2015	41.32 %	22.03 %	15.35 %
Q1 2016	42.51 %	23.29 %	17.20 %
Q2 2016	43.49 %	24.24 %	18.50 %
Q3 2016	44.66 %	25.57 %	19.88 %
Q4 2016	46.07 %	24.94 %	19.47 %
2016	46.07 %	24.94 %	19.47 %
Q1 2017	46.32 %	26.38 %	21.29 %
Q2 2017	46.38 %	27.68 %	22.38 %
Q3 2017	46.73 %	29.19 %	24.08 %
Q4 2017	46.13 %	30.34 %	25.30 %
2017	46.13 %	30.34 %	25.30 %
Q1 2018	44.93 %	28.26 %	22.97 %
Q2 2018	42.33 %	24.50 %	18.99 %
Q3 2018	39.86 %	21.41 %	15.49 %
Q4 2018	36.95 %	18.60 %	12.00 %
2018	36.95 %	18.60 %	12.00 %
Q1 2019	35.60 %	17.66 %	9.96 %
Q2 2019	35.23 %	17.77 %	9.57 %
Q3 2019	35.16 %	17.58 %	8.93 %
Q4 2019	35.77 %	19.73 %	10.66 %
2019	35.77 %	19.73 %	10.66 %
Q1 2020	34.79 %	18.58 %	9.44 %
Q2 2020	33.85 %	18.13 %	9.05 %
Q3 2020	34.50 %	19.13 %	9.55 %
Q4 2020	34.12 %	16.71 %	6.13 %
2020	34.12 %	16.71 %	6.13 %
Q1 2021	34.76 %	18.09 %	7.62 %
Q2 2021	35.67 %	19.32 %	8.88 %
Q3 2021	35.20 %	18.83 %	8.64 %
Q4 2021	36.12 %	21.04 %	11.79 %
2021	36.12 %	21.04 %	11.79 %
Q1 2022	36.72 %	21.66 %	12.54 %
Q2 2022	37.15 %	22.13 %	12.98 %
Q3 2022	37.06 %	22.17 %	12.42 %
Q4 2022	35.98 %	20.37 %	11.03 %
2022	35.98 %	20.37 %	11.03 %
Q1 2023	35.84 %	20.47 %	11.04 %
Q2 2023	35.54 %	19.47 %	10.07 %
Q3 2023	36.12 %	20.16 %	11.48 %
Q4 2023	36.65 %	20.50 %	12.24 %
2023	36.65 %	20.29 %	12.24 %
Q1 2024	36.72 %	20.57 %	12.78 %
Q2 2024	37.61 %	21.81 %	14.29 %
Q3 2024	37.78 %	-	14.70 %

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
2014	41.76 %	22.14 %	17.13 %
2015	41.32 %	22.03 %	15.35 %
2016	46.07 %	24.94 %	19.47 %
2017	46.13 %	30.34 %	25.30 %
2018	36.95 %	18.60 %	12.00 %
2019	35.77 %	19.73 %	10.66 %
2020	34.12 %	16.71 %	6.13 %
2021	36.12 %	21.04 %	11.79 %
2022	35.98 %	20.37 %	11.03 %
2023	36.65 %	20.29 %	12.24 %

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
Q1 2015	42.48 %	21.43 %	14.17 %
Q2 2015	41.14 %	21.75 %	14.62 %
Q3 2015	39.26 %	17.88 %	11.96 %
Q4 2015	42.25 %	25.38 %	19.75 %
Q1 2016	46.50 %	26.86 %	21.08 %
Q2 2016	45.01 %	25.49 %	19.84 %
Q3 2016	44.80 %	24.50 %	18.81 %
Q4 2016	47.75 %	23.08 %	18.25 %
Q1 2017	47.43 %	32.36 %	28.09 %
Q2 2017	45.27 %	30.84 %	24.28 %
Q3 2017	46.32 %	30.89 %	26.02 %
Q4 2017	45.49 %	27.52 %	22.96 %
Q1 2018	42.69 %	24.11 %	18.82 %
Q2 2018	33.82 %	14.42 %	6.86 %
Q3 2018	36.08 %	18.15 %	11.56 %
Q4 2018	34.83 %	17.24 %	10.20 %
Q1 2019	37.45 %	20.42 %	10.95 %
Q2 2019	32.33 %	15.01 %	5.37 %
Q3 2019	35.77 %	17.35 %	8.83 %
Q4 2019	37.06 %	25.11 %	16.42 %
Q1 2020	33.62 %	15.88 %	6.12 %
Q2 2020	27.38 %	12.22 %	2.82 %
Q3 2020	37.81 %	21.04 %	10.67 %
Q4 2020	35.42 %	16.33 %	4.22 %
Q1 2021	35.75 %	20.37 %	10.64 %
Q2 2021	34.26 %	19.51 %	9.69 %
Q3 2021	35.37 %	18.67 %	9.16 %
Q4 2021	38.73 %	25.18 %	17.07 %
Q1 2022	38.02 %	22.74 %	13.56 %
Q2 2022	36.34 %	21.69 %	11.91 %
Q3 2022	35.19 %	19.15 %	7.30 %
Q4 2022	34.56 %	18.22 %	11.30 %
Q1 2023	37.23 %	22.77 %	13.21 %
Q2 2023	35.06 %	17.54 %	7.91 %
Q3 2023	37.46 %	21.82 %	13.19 %
Q4 2023	36.72 %	19.74 %	14.10 %
Q1 2024	37.42 %	22.82 %	15.22 %
Q2 2024	38.91 %	22.94 %	14.62 %
Q3 2024	38.10 %	-	14.88 %

Per Share Data (Riyal)

Compared With The

Period	Shares Outstanding (M)	EPS (Riyal)	Adjusted EPS (Riyal)	Book Value (BV)
Q1 2015	90.00	1.72	1.56	14.74
Q2 2015	90.00	1.73	1.58	14.63
Q3 2015	90.00	1.79	1.63	14.86
Q4 2015	90.00	1.83	1.68	15.48
Q1 2016	90.00	1.95	1.97	16.15
Q2 2016	90.00	2.15	2.21	15.76
Q3 2016	90.00	2.53	2.48	16.26
Q4 2016	90.00	2.50	2.52	16.85
Q1 2017	90.00	2.80	2.79	17.78
Q2 2017	90.00	2.97	2.93	17.24
Q3 2017	90.00	3.15	3.22	18.05
Q4 2017	90.00	3.28	3.41	18.80
Q1 2018	90.00	2.98	3.11	19.41
Q2 2018	90.00	2.41	2.54	17.98
Q3 2018	90.00	1.92	2.05	18.34
Q4 2018	90.00	1.58	1.58	17.79
Q1 2019	90.00	1.32	1.32	18.07
Q2 2019	90.00	1.28	1.28	16.24
Q3 2019	90.00	1.22	1.22	16.54
Q4 2019	90.00	1.63	1.48	16.91
Q1 2020	90.00	1.46	1.31	16.57
Q2 2020	90.00	1.36	1.21	16.65
Q3 2020	90.00	1.66	1.33	17.25
Q4 2020	90.00	1.47	0.90	19.94
Q1 2021	90.00	1.84	1.27	19.89
Q2 2021	90.00	2.29	1.72	20.42
Q3 2021	90.00	2.24	1.86	20.86
Q4 2021	90.00	2.87	2.76	20.74
Q1 2022	90.00	3.21	3.09	21.70
Q2 2022	90.00	3.45	3.34	22.47
Q3 2022	90.00	3.38	3.27	21.96
Q4 2022	90.00	3.05	3.05	22.11
Q1 2023	97.68	2.93	2.93	32.03
Q2 2023	97.68	2.76	2.76	32.07
Q3 2023	97.68	3.33	3.33	32.64
Q4 2023	97.68	3.69	3.69	32.79
Q1 2024	97.68	3.94	3.94	34.02
Q2 2024	97.68	4.54	4.54	34.51
Q3 2024	97.68	4.82	4.82	34.96

Period	Shares Outstanding (M)	EPS (Riyal)	Adjusted EPS (Riyal)	Book Value (BV)
2014	90.00	1.63	1.63	14.15
2015	90.00	1.83	1.68	15.48
2016	90.00	2.50	2.52	16.85
2017	90.00	3.28	3.41	18.80
2018	90.00	1.58	1.58	17.79
2019	90.00	1.63	1.48	16.91
2020	90.00	1.47	0.90	19.94
2021	90.00	2.87	2.76	20.74
2022	90.00	3.05	3.05	22.11
2023	97.68	3.69	3.69	32.79

Multiple Ratios (End of Period Price)

Compared With The

Period	P/E	Adjusted P/E	Price/book
Q1 2015	40.15	44.08	4.67
Q2 2015	45.84	50.27	5.43
Q3 2015	32.29	35.31	3.88
Q4 2015	27.26	29.73	3.23
Q1 2016	27.46	27.14	3.31
Q2 2016	28.54	27.81	3.89
Q3 2016	21.29	21.71	3.31
Q4 2016	27.05	26.85	4.01
Q1 2017	25.95	25.99	4.08
Q2 2017	26.81	27.16	4.62
Q3 2017	24.63	24.12	4.30
Q4 2017	21.93	21.10	3.82
Q1 2018	24.80	23.77	3.80
Q2 2018	28.42	26.97	3.81
Q3 2018	22.92	21.46	2.39
Q4 2018	25.39	25.39	2.25
Q1 2019	32.81	32.81	2.40
Q2 2019	34.90	34.90	2.76
Q3 2019	36.10	36.10	2.66
Q4 2019	25.93	28.53	2.50
Q1 2020	28.43	31.66	2.50
Q2 2020	31.13	34.94	2.55
Q3 2020	30.78	38.40	2.97
Q4 2020	35.71	58.36	2.63
Q1 2021	31.13	45.10	2.88
Q2 2021	37.67	50.14	4.22
Q3 2021	34.24	41.38	3.68
Q4 2021	28.37	29.55	3.93
Q1 2022	34.32	35.59	5.07
Q2 2022	34.85	36.05	5.35
Q3 2022	50.66	52.45	7.81
Q4 2022	52.67	52.67	7.27
Q1 2023	52.51	52.51	4.81
Q2 2023	60.71	60.71	5.23
Q3 2023	42.86	42.86	4.37
Q4 2023	46.59	46.59	5.24
Q1 2024	42.49	42.49	4.92
Q2 2024	34.08	34.08	4.49
Q3 2024	33.39	33.39	4.61

Period	P/E	Adjusted P/E	Price/book
2014	45.25	45.25	5.23
2015	27.26	29.73	3.23
2016	27.05	26.85	4.01
2017	21.93	21.10	3.82
2018	25.39	25.39	2.25
2019	25.93	28.53	2.50
2020	35.71	58.36	2.63
2021	28.37	29.55	3.93
2022	52.67	52.67	7.27
2023	46.60	46.60	5.24

Business Segments (Million)

Compared With The

Period	Medical Services	Medicine and Pharmaceutical Products
Q1 2015	224.02	16.38
Q2 2015	228.38	16.85
Q3 2015	215.41	8.52
Q4 2015	257.40	18.49
Q1 2016	276.15	8.88
Q2 2016	277.42	10.93
Q3 2016	265.04	8.13
Q4 2016	307.51	8.73
Q1 2017	239.94	62.81
Q2 2017	229.31	58.90
Q3 2017	235.08	60.17
Q4 2017	241.44	84.43
Q1 2018	236.76	71.84
Q2 2018	205.73	67.39
Q3 2018	218.43	62.50
Q4 2018	228.74	89.55
Q1 2019	239.22	81.93
Q2 2019	210.95	75.06
Q3 2019	232.55	68.79
Q4 2019	259.40	84.20
Q1 2020	227.83	86.77
Q2 2020	166.96	80.60
Q3 2020	260.50	90.30
Q4 2020	309.74	95.55
Q1 2021	378.70	115.97
Q2 2021	374.54	116.29
Q3 2021	412.23	131.88
Q4 2021	472.23	103.34
Q1 2022	470.53	138.87
Q2 2022	475.30	108.52
Q3 2022	438.86	162.03
Q4 2022	547.10	146.77
Q1 2023	530.59	186.05
Q2 2023	513.01	157.40
Q3 2023	518.40	231.43
Q4 2023	597.28	208.74
Q1 2024	574.66	209.40
Q2 2024	550.68	214.50
Q3 2024	628.19	219.55

Period	Medical Services	Medicine and Pharmaceutical Products
2014	797.83	62.05
2015	925.20	60.24
2016	1,126.12	36.67
2017	945.78	266.30
2018	889.66	291.28
2019	942.12	309.97
2020	965.03	353.22
2021	1,637.71	467.47
2022	1,931.79	556.20
2023	2,159.27	783.63

Analysts Estimates (Million)

Item	Q3 2024 (e)	Q3 2024 (a)	Change‬
Average	125.18	126.15	0.78 %

Estimates vs Actual (Million)

Item	Q3 2024 (e)	Q3 2024 (a)	Change
AlJazira Capital	125.90	126.15	0.2 %
SNB Capital	128.00	126.15	(1.4) %
Hermes	130.00	126.15	(3.0) %
OSOOL AND BAKHEET	121.33	126.15	4.0 %
Goldman Sachs	120.14	126.15	5.0 %
Al Rajhi Capital	134.00	126.15	(5.9) %
U-Capital	116.90	126.15	7.9 %

Financial Ratios

	Current
Market Cap (M Riyal)	14,808.29
Enterprise Value (EV) (M)	16,727.89
Shares Outstanding ((M))	97.68
EPS ( Riyal) (TTM)	4.82
Book Value (BV) ( Riyal)	34.96
Par Value ( Riyal)	10.00
Adjusted P/E (Last12)	31.44
P/E (TTM)	31.44
Price/book	4.34
Return on Average Assets (%) (TTM)	7.5
Return on Average Equity (%) (TTM)	14.3

Company	Estimated	Actual	Change
CENOMI RETAIL	(94.00)	17.71	118.8 %
CENOMI CENTERS	259.80	334.65	28.8 %
DALLAH HEALTH	125.18	126.15	0.8 %
ALMAWARID	25.80	17.10	(33.7 %)
MIS	35.23	16.73	(52.5 %)
SPIMACO	23.50	(8.03)	(134.2 %)

Company	Estimated	Actual	Change
CENOMI RETAIL	(94.00)	17.71	118.8 %
CENOMI CENTERS	259.80	334.65	28.8 %
DALLAH HEALTH	125.18	126.15	0.8 %

Company	Estimated	Actual	Change
SPIMACO	23.50	(8.03)	(134.2 %)
MIS	35.23	16.73	(52.5 %)
ALMAWARID	25.80	17.10	(33.7 %)

Twitter

Facebook

Linked in

Comments {{getCommentCount()}}

Be the first to comment

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

Sorry: the validity period has ended to comment on this news

Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.

Dallah 9M 2024 profit soars 45% to SAR 357.3M; Q3 at SAR 126.2M

View other reports

Financials (M)

Current Quarter Comparison (M)

Financial results (Million)

Financial results (Million)

Profit Performance (Million)

Profit Performance (Million)

Profitability

Profitability

Per Share Data (Riyal)

Per Share Data (Riyal)

Multiple Ratios (End of Period Price)

Ratios And Multiples

Business Segments (Million)

Revenue by Business Segment (Latest) 2024 Q3

Analysts Estimates (Million)

Analysts Estimates (Million)

Estimates vs Actual (Million)

Estimates Accuracy

Financial Ratios

Share Price

Dallah Healthcare Co. (DALLAH HEALTH)

Quarterly Actuals vs Estimates 10/11/202411/11/2024

Comments {{getCommentCount()}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}}

×

Dallah 9M 2024 profit soars 45% to SAR 357.3M; Q3 at SAR 126.2M

View other reports

Financials (M)

Current Quarter Comparison (M)

Financial results (Million)

Financial results (Million)

Profit Performance (Million)

Profit Performance (Million)

Profitability

Profitability

Per Share Data (Riyal)

Per Share Data (Riyal)

Multiple Ratios (End of Period Price)

Ratios And Multiples

Business Segments (Million) Q3 2024

Revenue by Business Segment (Latest) 2024 Q3

Analysts Estimates (Million)

Analysts Estimates (Million)

Estimates vs Actual (Million)

Estimates Accuracy

Financial Ratios

Share Price

Dallah Healthcare Co. (DALLAH HEALTH)

Quarterly Actuals vs Estimates 10/11/202411/11/2024

Comments {{getCommentCount()}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}}

Business Segments (Million)